한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제38권3호
  • /
  • Pages.127-134
  • /
  • 2021
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

Clinical Efficacy of Oclacitinib and Lokivetmab in Dogs with Canine Atopic Dermatitis

  • Lee, Sora (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Yun, Taesik (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Koo, Yoonhoi (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Chae, Yeon (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Lee, Dohee (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Choi, Dongjoon (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Choi, Yujin (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Kim, Hakhyun (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Yang, Mhan-Pyo (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Kang, Byeong-Teck (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University)
  • 투고 : 2021.03.02
  • 심사 : 2021.05.28
  • 발행 : 2021.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Canine atopic dermatitis (CAD) is a genetically predisposed inflammatory and pruritic skin disease presenting characteristic clinical features in dogs. Despite oclacitinib and lokivetmab being commonly used, no study has compared their efficacies in CAD. This study aimed to compare the efficacy, safety, and control of CAD-associated pruritus and skin lesions between oclacitinib and lokivetmab. It also investigated whether switching to lokivetmab from oclacitinib or prednisolone had any benefits. Twenty-five client-owned dogs, newly diagnosed with CAD, were allocated to the oclacitinib (n = 20) and lokivetmab (n = 5) groups and administered oclacitinib (0.4-0.6 mg/kg orally, twice daily for 14 days, then once daily) and lokivetmab (2 mg/kg subcutaneously, every month) for 8 weeks, respectively. The switching group included five dogs previously administered with oclacitinib (n = 4) or prednisolone (n = 1) who were switched to lokivetmab directly at the start of the study. The pruritus visual analog scale (PVAS) and Canine Atopic Dermatitis Extent and Severity Index (CADESI-04) values were surveyed at weeks 0, 4, and 8. Oclacitinib and lokivetmab significantly reduced the PVAS and CADESI-04 scores. Switching from oclacitinib or prednisolone to lokivetmab maintained the severity of pruritus (4 weeks: p = 0.068; 8 weeks: p = 0.068) and dermatitis (4 weeks: p = 0.144; 8 weeks: p = 0.068) at the levels measured at baseline. Thus, both oclacitinib and lokivetmab reduced CAD-associated pruritus by a similar degree. Switching to lokivetmab maintained the severity of pruritus and dermatitis at the same level as the previous treatment.

키워드

과제정보

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1A2C1012058).

참고문헌

  1. Carmi-Levy I, Homey B, Soumelis V. A modular view of cytokine networks in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41: 245-253. https://doi.org/10.1007/s12016-010-8239-6
  2. Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol 2015; 26: 171-179, e35. https://doi.org/10.1111/vde.12194
  3. Cosgrove SB, Wren JA, Cleaver DM, Martin DD, Walsh KF, Harfst JA, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24: 479-e114. https://doi.org/10.1111/vde.12047
  4. Fleck TJ, Bammert G, Shelly J, Fici G, Walters RR, Mahabir S, et al. Identification and characterization of ZTS-00103289, a monoclonal antibody neutralizing interleukin-31-mediated pruritus, in beagle dogs. Vet Dermatol 2015; 26: 147.
  5. Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol 2014; 25: 512-518, e86. https://doi.org/10.1111/vde.12166
  6. Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 2014; 37: 317-324. https://doi.org/10.1111/jvp.12101
  7. Gonzales AJ, Humphrey WR, Messamore JE, Fleck TJ, Fici GJ, Shelly JA, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 2013; 24: 48-53.e11-e12. https://doi.org/10.1111/j.1365-3164.2012.01098.x
  8. Gortel K. An embarrassment of riches: an update on the symptomatic treatment of canine atopic dermatitis. Can Vet J 2018; 59: 1013-1016.
  9. Gow DJ, Jackson H, Forsythe P, Nuttall T, Gow AG, Mellanby RJ, et al. Measurement of serum Interleukin 34 (IL-34) and correlation with severity and pruritus scores in client-owned dogs with atopic dermatitis. Vet Dermatol 2020; 31: 359-e94. https://doi.org/10.1111/vde.12873
  10. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol 2006; 114: 207-208. https://doi.org/10.1016/j.vetimm.2006.08.013
  11. Hensel P, Santoro D, Favrot C, Hill P, Griffin C. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC Vet Res 2015; 11: 196. https://doi.org/10.1186/s12917-015-0515-5
  12. Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol 2015; 115: 341-384. https://doi.org/10.1016/j.anai.2015.07.019
  13. Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 2015; 26: 23-30, e7-e8. https://doi.org/10.1111/vde.12186
  14. Marsella R, Ahrens K, Sanford R. Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using beagle dogs. Vet Dermatol 2018; 29: 69-e28. https://doi.org/10.1111/vde.12500
  15. Michels GM, Ramsey DS, Walsh KF, Martinon OM, Mahabir SP, Hoevers JD, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 2016; 27: 478-e129. https://doi.org/10.1111/vde.12376
  16. Moyaert H, Van Brussel L, Borowski S, Escalada M, Mahabir SP, Walters RR, et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 2017; 28: 593-e145. https://doi.org/10.1111/vde.12478
  17. Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al.; International Committee on Allergic Diseases of Animals. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 2015; 11: 210. https://doi.org/10.1186/s12917-015-0514-6
  18. Olivry T, Mueller RS; International Task Force on Canine Atopic Dermatitis. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003; 14: 121-146. https://doi.org/10.1046/j.1365-3164.2003.00335.x
  19. Olivry T, Saridomichelakis M, Nuttall T, Bensignor E, Griffin CE, Hill PB; International Committe on Allergic Diseases of Animals (ICADA). Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. Vet Dermatol 2014; 25: 77-85, e25. https://doi.org/10.1111/vde.12107
  20. Olivry T, Steffan J, Fisch RD, Prelaud P, Guaguere E, Fontaine J, et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002; 221: 370-377. https://doi.org/10.2460/javma.2002.221.370
  21. Rybnicek J, Lau-Gillard PJ, Harvey R, Hill PB. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 2009; 20: 115-122. https://doi.org/10.1111/j.1365-3164.2008.00728.x
  22. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282: 20059-20063. https://doi.org/10.1074/jbc.R700016200
  23. Walters RR, Boucher JP, Paquette JA, Birkholz PJ, Mahabir S, Dunham S, et al. Laboratory dose titration efficacy study of ZTS-00103289, a caninized antiinterleukin-31 monoclonal antibody, in a canine model of IL-31-induced pruritus. Vet Dermatol 2015; 26: 145.
  24. Wood SH, Clements DN, Ollier WE, Nuttall T, McEwan NA, Carter SD. Gene expression in canine atopic dermatitis and correlation with clinical severity scores. J Dermatol Sci 2009; 55: 27-33. https://doi.org/10.1016/j.jdermsci.2009.03.005